A clinical validity study published in Clinical Cancer Research found that landmark ctDNA molecular response is an early predictor of immunotherapy outcomes in lung cancer. Additionally, discussion is highlighting the role of antibody-drug conjugates (ADCs) in treating patients with lung cancer and brain metastases, focusing on recent data and guideline recommendations.
“not all EGFR "positive" lung cancers are the same.”
— @lungoncdoc · EGFR+ NSCLC Heterogeneity · View post ↗📌 Amplified by @KolPulseAI
“Landmark ctDNA molecular response represents an early predictor of immunotherapy outcomes in lung cancer: A clinical validity study”
— @CCR_AACR · ctDNA as a predictive biomarker · View post ↗
“ADCs are reshaping options for patients with breast & lung cancers with #BrainMets.”
— @PeerView · ADCs for Brain Metastases · View post ↗A SWOG S1007 (RxPONDER) analysis found that premenopausal patients with HR-positive, HER2-negative, node-positive breast cancer and low baseline AMH (<10 pg/ml) did not derive IDFS or DRFS benefit from adjuvant chemotherapy. Separately, data from the WSG ADAPT-HR+/HER2− and ADAPTcycle trials showed low post-endocrine Ki67 levels are associated with improved outcomes, helping optimize patient selection for chemotherapy omission. Additionally, ctDNA was noted to be superior to tumor tissue biopsy for detecting acquired ESR1 mutations in metastatic HR+ disease.
“Premenopausal patients aged <55 years with low baseline AMH <10 pg/ml did not have IDFS or DRFS improvement with chemotherapy.”
— @to_be_elizabeth · SWOG S1007 (RxPONDER) · View post ↗“Low postendocrine Ki67 levels are associated with improved outcomes in N0-1 HR-positive/HER2-negative eBC.”
— @to_be_elizabeth · ADAPT Trials · View post ↗
“in patients with metastatic HR+ breast cancer, ESR1 mutations (acquired resistance mutation to aromatase inhibitors) is better detected by ctDNA than testing tumor tissue.”
— @allisonoconn · ESR1 Detection · View post ↗A study published in JCO on first-line disitamab vedotin plus tislelizumab and S-1 in HER2-overexpressing advanced gastric/GEJ adenocarcinoma showed an 89.5% ORR and 31.9-month median OS. The design for the phase 3 LUCERNA trial was also shared, evaluating zolbetuximab with pembrolizumab and chemotherapy in CLDN18.2+, HER2-, PD-L1+ gastric/GEJ cancer. Additionally, the first patient was dosed in a trial of an off-the-shelf therapeutic vaccine for esophageal cancer.
“First-line disitamab vedotin + tislelizumab + S-1 showed impressive activity in HER2-overexpressing advanced gastric/GEJ adenocarcinoma @JCO_ASCO • ORR 89.5% • mPFS 13.8 mo • mOS 31.9 mo”
— @Dr_ElvinaA · Gastric Cancer Combination · View post ↗📌 Amplified by @KolPulseAI
“Pleased to share the design of the phase 3 LUCERNA trial of zolbetuximab + pembrolizumab + chemotherapy in CLDN18.2+, HER2-, PD-L1+ gastric/GEJ cancer. Enrollment is nearly complete.”
— @KoheiShitara · LUCERNA Trial Design · View post ↗📌 Amplified by @KolPulseAI
“This is a clinical trial for an off-the-shelf therapeutic vaccine in esophageal cancer, given alongside chemo-immunotherapy and surgery.”
— @DrSamuelBHume · Esophageal Cancer Vaccine · View post ↗
“Editorial in @NEJM by @ShivanSivakumar Breaking the RAS Barrier in #PancreaticCancer”
— @Aiims1742 · RAS in Pancreatic Cancer · View post ↗📌 Amplified by @KolPulseAI
Track oncology’s top KOLs in your specialty
Create a free account, pick the tumor types you cover, and go beyond the tweet — the intelligence pharma teams use to map influence and prepare for engagement:
- ✓Enhanced KOL profiles
- ✓Pharma influence & potential advisory-board patterns
- ✓2025 Open Payments financial analysis
- ✓Social-media sentiment & trend signals
Clinical commentary highlights the risk of urothelial cancer recurrence in the urethra post-cystectomy, even with negative washings or imaging. Other areas of focus for the GU oncology community include prostate cancer survivorship, specifically the neurocognitive effects of Androgen Deprivation Therapy (ADT) and lifestyle interventions, alongside discussions on the appropriate use and limitations of AI in kidney cancer research.
Live from the meetingKCRS26 — Kidney Cancer Research Summit 2026: LITESPARK-022 QoL data, KIM-1 as an RCC biomarker, adjuvant pembrolizumab recurrence patterns, and AI in kidney cancer.View coverage →
“Negative urethral washings / imaging don’t always mean the urethra is clear.. Urothelial cancer is sticky and can stick around even w/ neg margins post Cystectomy .”
— @LauraBukavinaMD · Post-Cystectomy Surveillance · View post ↗
“Looking forward to learning from her lecture on “Neurocognitive Effects of Androgen Deprivation Therapy and Prostate Cancer Survivorship Science.””
— @SakditadMD · Prostate Cancer Survivorship · View post ↗
“AI can find patterns humans miss. It can also reproduce every bias hidden in our data. In kidney cancer research, the question is not whether to use AI, but where we should refuse to trust it.”
— @DrYukselUrun · AI in Kidney Cancer · View post ↗A new manuscript details data on an investigational FcRH5 x CD3 T-cell engager for relapsed/refractory multiple myeloma. Separately, a study in Blood Cancer Journal found that high WEE1 expression is independently linked to poor survival. The myeloma/hematology community is also sharing clinical guidance on the treatment of plasma cell leukemia, as published in Blood.
“longly awaited data and manuscript on FcRH5 x CD3 TCE in relapsed refractory myeloma.”
— @NBahlis · FcRH5 x CD3 TCE · View post ↗
“High WEE1 expression is independently linked to poor survival in multiple myeloma [Feb 20, 2025]”
— @mtmdphd · WEE1 Expression · View post ↗
“How I treat plasma cell leukemia”
— @HadidiSamer · Plasma Cell Leukemia · View post ↗📌 Amplified by @KolPulseAI
“Highly recommended: CAR T-cell therapy related Toxicities including Parkinsonism, Immune Effector Cell-associated Enterocolitis (#IECEC) and more.”
— @phsiao4 · CAR T-cell Toxicities · View post ↗The BTK A428D mutation is being highlighted as a significant resistance mechanism in CLL, raising questions about the utility of BTK degraders as continuous monotherapy in early-line disease. Separately, a systematic review is focusing on asciminib as a first-line therapy in chronic myeloid leukemia, and a multicenter retrospective study evaluated upfront autologous stem cell transplantation in first complete remission for advanced-stage extra-nodal NK/T-cell lymphoma.
“BTK A428D is a very, very bad mutation and one reason why I would be hesitant to think about using a BTK degrader as a continuous monotherapy in early-line CLL”
— @calliecoombsmd · BTK resistance in CLL · View post ↗
“Highly cited review article in Blood Research: "Asciminib as first‑line therapy in chronic myeloid leukemia: a systematic review" by Jae Joon Han et al.”
— @Blood_Res · Asciminib in CML · View post ↗
“Upfront Autologous Stem Cell Transplantation in First Complete Remission for Advanced-Stage Extra-Nodal NK/T-Cell Lymphoma: A Multicenter Retrospective Study”
— @MostafaFaisal14 · ASCT in NK/T-Cell Lymphoma · View post ↗